RecruitingPhase 2NCT06981078
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
A Phase 2b Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess Efficacy and Safety of Verekitug (UPB-101) in Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Sponsor
Upstream Bio Inc.
Enrollment
666 participants
Start Date
Jul 2, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to assess the efficacy and safety of verekitug (UPB-101) in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), an inflammatory lung disease.
Eligibility
Min Age: 40 YearsMax Age: 85 Years
Inclusion Criteria6
- Physician diagnosis of COPD for \>12 months.
- Current or former smokers with a smoking history of 10 pack-years or more.
- Post-bronchodilator FEV1/ Forced Vital Capacity (FVC) ratio \<0.70 and predicted post-bronchodilator FEV1 \>30% and ≤80%.
- Modified Medical Research Council dyspnea scale Grade ≥2.
- Background triple therapy (Inhaled Corticosteroid \[ICS\], Long-Acting Beta Agonist \[LABA\], Long-Acting Muscarinic Antagonist \[LAMA\]) for 3 months before randomization with a stable dose of medications for 1 or more months prior to Visit 1.
- Are ≥80% compliant with background therapy during the screening period.
Exclusion Criteria8
- Moderate or severe exacerbation of COPD within 4 weeks prior to or during the screening period.
- Respiratory tract infection within 4 weeks prior to or during the screening period.
- Treatment with oxygen of \>4 liters/minute. Nocturnal oxygen use for sleep apnea is allowed.
- Systemic or biologic immunosuppressant therapy to treat inflammatory disease or autoimmune disease within 24 weeks or 5 half-lives prior to Visit 1, whichever is longer, with the exception of oral corticosteroids. Treatment with cyclophosphamide and rituximab within 12 months of Visit 1.
- Current diagnosis of asthma according to the 2023 Global Initiative for Asthma guidelines or other accepted guidelines
- History or evidence of a clinically meaningful pulmonary condition other than COPD (e.g., pulmonary fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension, bronchiectasis, Churg-Strauss Syndrome) or another diagnosed pulmonary or systemic disease associated with elevated peripheral eosinophil counts.
- Chronic hypercapnia requiring Bilevel Positive Airway Pressure (BiPAP). Participants requiring BiPAP periodically for an acute COPD exacerbation are not excluded.
- Any of the following in the previous 6 months prior to Visit 1: acute myocardial infarction, transient ischemic attack or stroke, hospitalization for any cardiovascular or cerebrovascular event, pulmonary embolism, deep vein thrombosis and cardiac arrhythmias including paroxysmal (e.g., intermittent). Participants with persistent atrial fibrillation as defined by continuous atrial fibrillation for at least 6 months and controlled with a rate control strategy (i.e., selective beta blocker, calcium channel blocker, pacemaker placement, digoxin or ablation therapy) and stable appropriate level of anticoagulation for at least 6 months may be considered for inclusion.
Interventions
DRUGVerekitug
Verekitug (UPB-101) formulated solution
OTHERPlacebo
Matching Placebo to Verekitug (UPB-101)
Locations(325)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06981078
Related Trials
A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation
NCT070739506 locations
Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo
NCT0706982912 locations
A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease
NCT066032467 locations
Different Inspiratory Muscle Trainings in Patients With COPD
NCT074066591 location
Predicting Risk Factors for Exacerbation of Chronic Obstructive Pulmonary Disease
NCT034506031 location